Search

Savara Inc

Suletud

SektorTervishoid

4.45 -6.12

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.44

Max

4.57

Põhinäitajad

By Trading Economics

Sissetulek

-2.9M

-40M

Aktsiakasum

-0.16

Töötajad

70

EBITDA

-2.9M

-40M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+139.1% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

10. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-182M

992M

Eelmine avamishind

10.57

Eelmine sulgemishind

4.45

Savara Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. okt 2026, 22:26 UTC

Savara Inc shares traded lower in after-market hours, reflecting ongoing weakness amid broader market concerns over rising U.S. import and export prices.

15. okt 2026, 23:06 UTC

Savara Inc's shares are advancing in after-market trading, gaining ground since Thursday's close, with a cumulative return peaking at just under 1.9%.

14. okt 2026, 19:36 UTC

Savara Inc shares fell modestly on Wednesday, retracing from an early peak and remaining under pressure below their 20-day moving average.

13. okt 2026, 20:13 UTC

Savara Inc shares advanced in after-market trading, continuing their upward trend since Tuesday's close, though still below the 20-day moving average.

12. okt 2026, 19:36 UTC

Social Media

Savara Inc shares are declining, having pulled back from an earlier high in pre-market hours, and are currently below their 20-day moving average.

9. okt 2026, 19:55 UTC

Social Media

JPMorgan sets a price target of $12 for Savara Inc, noting catalysts including anticipated UK approval in Q4 and a MAA in Q1 for molgramostim.

8. okt 2026, 23:25 UTC

Savara Inc shares advanced during after-market hours on Thursday, settling at a solid gain.

7. okt 2026, 20:01 UTC

News
Social Media

Savara Inc shares are trading sharply higher as JP Morgan initiated coverage with an Overweight rating and a $12 price target ahead of its PDUFA date.

6. okt 2026, 20:00 UTC

Savara Inc shares fell, breaking a trend of higher daily closes, indicating a shift in momentum following Monday's close.

2. okt 2026, 20:01 UTC

Savara Inc shares fell sharply, experiencing significant volatility and trading below their 20-day moving average amid high market volume.

1. okt 2026, 19:46 UTC

Social Media

Savara Inc shares are trading lower as heightened short interest and increased volume coincide with the approach of its PDUFA date for molgramostim.

30. sept 2026, 21:03 UTC

Social Media

Savara Inc shares are trading higher in after-market hours amid speculation of a short squeeze ahead of its PDUFA date for molgramostim, with a market cap of $1 billion.

28. sept 2026, 20:02 UTC

Social Media

Savara Inc is trading higher amid notable social media activity and unusual options bets, with a PDUFA date set for November 22.

25. sept 2026, 20:07 UTC

Savara Inc shares fell sharply, continuing the downward trend with a cumulative return in negative territory and remaining below its 20-day moving average.

24. sept 2026, 19:46 UTC

Savara Inc is trading higher, having previously peaked before a slight retracement, though it remains below its 20-day moving average.

23. sept 2026, 22:01 UTC

Savara Inc gained in after-market trading following a brief decline earlier in the session, though it remains below its 20-day moving average.

22. sept 2026, 20:05 UTC

Savara Inc's stock is declining sharply, moving from an initial gain to a notable drop, trading below its 20-day moving average.

21. sept 2026, 20:12 UTC

Savara Inc is advancing in after-market trading, positioned above its 20-day moving average and near the upper end of its one-month range.

18. sept 2026, 23:11 UTC

Savara Inc is trading modestly higher in after-market hours, reflecting the broader market's upward movement, with notable gains since Friday's close.

17. sept 2026, 23:11 UTC

Savara Inc is seeing a modest upward move in after-market trading, currently near the upper end of its one-month range.

16. sept 2026, 20:10 UTC

Savara Inc shares fell sharply today, continuing a decline since Tuesday and trading significantly below its 20-day moving average.

15. sept 2026, 20:07 UTC

Savara Inc shares are lower, impacted by a sharp decline in the NY Empire State Manufacturing Index and rising oil prices amid broader market weakness.

11. sept 2026, 20:08 UTC

Savara Inc. shares are trading lower today, continuing a decline since Thursday's close amid a broader market downturn.

10. sept 2026, 20:03 UTC

Savara Inc. shares are lower today, reflecting broader market conditions amid the European Central Bank's recent interest rate hike and inflation projections.

4. sept 2026, 19:26 UTC

Savara Inc shares are higher today, trading within a narrow range. The stock is currently near the lower end of its one-month range.

3. sept 2026, 20:02 UTC

Savara Inc shares are lower during Thursday's session, retracing from an earlier peak amid rising jobless claims that may affect Federal Reserve policy.

2. sept 2026, 20:08 UTC

Savara Inc. shares are higher today, driven by a significant upward trend in the Biotechnology sub-sector. No specific company news was identified.

1. sept 2026, 19:36 UTC

Savara Inc. shares are lower today, continuing a decline since Monday. The stock remains below its 20-day moving average amid rising inflation concerns.

31. aug 2026, 22:01 UTC

Savara Inc. shares rose in after-market trading, advancing since Monday's close, despite earlier pulling back from a session high. No specific news was identified.

28. aug 2026, 21:02 UTC

In after-market trading, Savara Inc. has increased following a flat start, indicating upward momentum despite remaining below its 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

Savara Inc Prognoos

Hinnasiht

By TipRanks

139.1% tõus

12 kuu keskmine prognoos

Keskmine 11.333 USD  139.1%

Kõrge 16 USD

Madal 9 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Savara Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

6

Osta

0

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat